FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	STAT
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Royal Mike A					2. Issuer Name and Ticker or Trading Symbol CADENCE PHARMACEUTICALS INC [CADX]						[(Ch	 Relationship of Reporting F (Check all applicable) Director Officer (give title 			erson(s) to Issuer 10% Owner Other (specify			
(Last)	`	rst) ARMACEUTIC	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/22/2007							X Officer (give title Other (specify below) VP						
12481 HIGH BLUFF DRIVE, SUITE 200					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street)	EGO CA	A	92130					or Griginal rank	va (mena #2e	,,,,,	Line	e) <mark>X</mark> Form fi	led by One	Repo	orting Person			
(City)	(Si	ate)	(Zip)									reisui	l					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)		ed (A) or tr. 3, 4 and	Beneficia	es Formally (D) (Following (I) (I		m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
						Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	tion(s)			(Instr. 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Date, To Country or Exercise (Month/Day/Year) if any		Code (ransaction of ode (Instr. Derivative		ve es d ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares							
Stock option (right to buy)	\$15.13	03/22/2007		A		25,000		(1)	03/21/2017	Common Stock	25,000	(2)	25,000)	D			

Explanation of Responses:

1. All of the shares of common stock subject to the option are immediately exercisable. 25% of the total number of shares of common stock subject to the option vest and are no longer subject to the Company's right to repurchase on March 22, 2008. 1/48th of the total number of shares of common stock subject to the option vest and are no longer subject to the Company's right to repurchase on the 1st of each month thereafter.

2. Not applicable to this transaction.

Remarks:

/s/ Jennifer M. Repine Attorney-in-fact

03/26/2007

** Signature of Reporting Person Da

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.